IN2012DN02304A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02304A
IN2012DN02304A IN2304DEN2012A IN2012DN02304A IN 2012DN02304 A IN2012DN02304 A IN 2012DN02304A IN 2304DEN2012 A IN2304DEN2012 A IN 2304DEN2012A IN 2012DN02304 A IN2012DN02304 A IN 2012DN02304A
Authority
IN
India
Prior art keywords
aging
arnox
disorders
recombinant
nadh oxidase
Prior art date
Application number
Other languages
English (en)
Inventor
James D Morre
Xiaoyu Tang
Sara Dick
Christiaan Meadows
Dorothy M Morre
Original Assignee
Nox Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nox Technologies Inc filed Critical Nox Technologies Inc
Publication of IN2012DN02304A publication Critical patent/IN2012DN02304A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90209—Oxidoreductases (1.) acting on NADH or NADPH (1.6), e.g. those with a heme protein as acceptor (1.6.2) (general), Cytochrome-b5 reductase (1.6.2.2) or NADPH-cytochrome P450 reductase (1.6.2.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IN2304DEN2012 2009-08-17 2010-08-17 IN2012DN02304A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23436809P 2009-08-17 2009-08-17
PCT/US2010/045745 WO2011022387A1 (en) 2009-08-17 2010-08-17 Cloning and expression of arnox protein transmembrane 9 superfamily (tm9sf), methods and utility

Publications (1)

Publication Number Publication Date
IN2012DN02304A true IN2012DN02304A (enExample) 2015-08-21

Family

ID=43607300

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2304DEN2012 IN2012DN02304A (enExample) 2009-08-17 2010-08-17

Country Status (7)

Country Link
US (1) US20120315629A1 (enExample)
EP (1) EP2467392A4 (enExample)
JP (1) JP2013502217A (enExample)
CN (1) CN102574889A (enExample)
CA (1) CA2771277A1 (enExample)
IN (1) IN2012DN02304A (enExample)
WO (1) WO2011022387A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011109525A1 (en) 2010-03-02 2011-09-09 Nox Technologies, Inc. Aging-Related Circulating Particle-Associated Lipoprotein B Oxidase (apoBNOX) and Inhibitors Thereof
CN105705642A (zh) * 2013-06-25 2016-06-22 摩-纽克企业 具有产量增加潜能的植物生长相关enox蛋白、序列和方法
CN114774418B (zh) * 2022-04-19 2023-11-14 深圳市人民医院 shRNA分子及其在敲低TM9SF2基因表达中的应用
CN115772574A (zh) * 2022-10-27 2023-03-10 华南农业大学 鸡tm9sf2基因鉴定方法及其膜外结构域的原核表达

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175787A1 (en) * 1997-10-28 2003-09-18 Incyte Corporation Vesicle membrane proteins
US20070203083A1 (en) * 2003-06-13 2007-08-30 Mootha Vamsi K Methods Of Regulating Metabolism And Mitochondrial Function
US7473531B1 (en) * 2003-08-08 2009-01-06 Colora Corporation Pancreatic cancer targets and uses thereof
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US8014957B2 (en) * 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
MX2009010492A (es) * 2007-03-30 2009-10-19 Abbott Lab Elementos de vector de expresion recombinante (reves) para mejorar la expresion de proteinas recombinantes en celulas huesped.
ES2587055T3 (es) * 2008-01-25 2016-10-20 Hansabiomed Ou Una nueva molécula asociada a tumores humanos metastásicos, métodos para detectar tanto el gen activado como la proteína y para interferir con la expresión génica

Also Published As

Publication number Publication date
US20120315629A1 (en) 2012-12-13
EP2467392A1 (en) 2012-06-27
WO2011022387A1 (en) 2011-02-24
JP2013502217A (ja) 2013-01-24
WO2011022387A8 (en) 2012-03-29
EP2467392A4 (en) 2013-06-19
CN102574889A (zh) 2012-07-11
CA2771277A1 (en) 2011-02-24

Similar Documents

Publication Publication Date Title
NO20092522L (no) Sammensetninger og fremgangsmater for a behandle kreft med cupredoxiner og CPG rikt DNA
CL2007003649A1 (es) Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70.
BRPI0811210A2 (pt) Agente de formação de imagem, composição farmacêutica, métodos de preparação de um agente de formação de imagem, de formação de imagem óptica in vivo do corpo de um mamífero e de detecção, avaliação do estágio, diagnóstico, monitoração da progressão da doença ou monitoração do tratamento de câncer colorretal do corpo de um mamífero, e, kit para a preparação da composição farmacêutica.
BRPI0809594A2 (pt) polipeptídeo, seqüência de ácido nucléico, vetor, hospedeiro, processo para a produção de um polipeptídeo, composição farmacêutica, uso de um polipeptídeo, método para prevenção, tratamento ou melhora de uma doença, em um indivíduo com necessidade do mesmo, kit, método para a identificação de um polipeptídeo(s)
WO2008108803A3 (en) Immune cell biosensors and methods of using same
WO2008103645A8 (en) Prostate cancer and melanoma antigens
MX2009003562A (es) Ensayo elisa para la deteccion de vegf.
EP2068929A4 (en) METHOD OF DETECTING AND TREATING SKIN DISORDERS
MX2013003929A (es) Biomarcadores de citoquina como marcadores predictivos de respuesta clinica para acetato de glatiramer.
WO2011156734A3 (en) Method of characterizing vascular diseases
MX2010004251A (es) Anticuerpo anti-bst2.
WO2005040421A3 (en) Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues
IN2012DN02304A (enExample)
NZ609567A (en) Markers of endothelial progenitor cells and uses thereof
ES3005161T3 (en) Diagnostic method of a skin showing signs of aging
MX2009001070A (es) Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma.
RU2013104137A (ru) Изоформы bard1 при раке легкого и колоректальном раке и их применение
WO2009091230A3 (ko) 유방암 모니터링,진단 및 스크리닝용 단백질 마커 및 이를 이용한 유방암 모니터링,진단 및 스크리닝 방법
CN104603616B (zh) 使用纤蛋白‑3和/或肌聚糖γ作为指标评价脂肪团的方法和评价脂肪团有效药物的方法
EP2539709A4 (en) MORBUS ALZHEIMER SPECIFIC CHANGES OF PROTEIN KINASE C EPSILON (PKC EPSILON) PROTEIN MIRRORS
MY148542A (en) A method for the assessment of cancer in a biological sample obtained from a subject
Shamsadini et al. Leopard syndrome
WO2011141153A8 (en) Methods for the diagnosis and prognosis of a tumor using bcat1 protein
WO2012144755A3 (ko) 리포칼린 2 발현 수준을 측정하는 경도 인지 장애 진단용 조성물, 키트 및 경도인지 장애 진단을 위한 정보 제공방법
ATE500275T1 (de) Antikörper gegen april als biomarker zur frühen prognose in lymphompatienten